The use of 68 Ga-PSMA PET/CT to stratify patients with PI-RADS 3 lesions according to clinically significant prostate cancer risk.
Jinhui YangYongxiang TangChuanchi ZhouMing ZhouJian LiShuo HuPublished in: The Prostate (2022)
Ga-PSMA PET/CT is potentially capable of stratifying men with PI-RADS 3 lesions according to the presence of csPCa and has better performance than the model established based on clinical and mpMRI features.